Abstract
| Original language | English |
|---|---|
| Pages (from-to) | e791-e800 |
| Number of pages | 10 |
| Journal | The Lancet HIV |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Developing tuberculosis vaccines for people with HIV : consensus statements from an international expert panel. / Miner, Maurine D.; Hatherill, Mark; Mave, Vidya et al.
In: The Lancet HIV, Vol. 9, No. 11, 11.2022, p. e791-e800.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Developing tuberculosis vaccines for people with HIV
T2 - consensus statements from an international expert panel
AU - Miner, Maurine D.
AU - Hatherill, Mark
AU - Mave, Vidya
AU - Gray, Glenda E.
AU - Nachman, Sharon
AU - Read, Sarah W.
AU - White, Richard G.
AU - Hesseling, Anneke
AU - Cobelens, Frank
AU - Patel, Sheral
AU - Frick, Mike
AU - Bailey, Theodore
AU - Seder, Robert
AU - Flynn, Joanne
AU - Rengarajan, Jyothi
AU - Kaushal, Deepak
AU - Hanekom, Willem
AU - Schmidt, Alexander C.
AU - Scriba, Thomas J.
AU - Nemes, Elisa
AU - Andersen-Nissen, Erica
AU - Landay, Alan
AU - Dorman, Susan E.
AU - Aldrovandi, Grace
AU - Cranmer, Lisa M.
AU - Day, Cheryl L.
AU - Garcia-Basteiro, Alberto L.
AU - Fiore-Gartland, Andrew
AU - Mogg, Robin
AU - Kublin, James G.
AU - Gupta, Amita
AU - Churchyard, Gavin
N1 - Funding Information: GC, JGK, AG, and MDM led and wrote the Review, with support from Austin Van Grack (Social & Scientific Systems) under the overall direction of Judith Currier and Joseph Eron (AIDS Clinical Trials Group), Glenda Gray (HIV Vaccine Trials Network), Sharon Nachman (International Maternal Paediatric Adolescent AIDS Clinical Trials network), and Peter Kim and Sarah Read (NIAID Division of Aids [DAIDS]). The ACTG, HVTN, and IMPAACT provided support for developing the consensus statements. Funding was provided by National Institutes of Health (NIH) grants (UM1 AI 068636, UM1 AI068614, 5UM1AI154463, and UM1 AI 068636 to GC; UM1 AI068614-14 to JGK; and NIH UM1 AI069465 to AG). We gratefully acknowledge the contribution of the people who participated in various sessions: Austin Van Grack (DLH Corporation, Atlanta, GA, USA); Abdou Fofana (Boston University, Boston, MA, USA); Adrienne Shapiro, Chandler Church, and Chetan Seshadri (University of Washington, Seattle, WA, USA); Ann Ginsberg (Gates Foundation, Seattle, WA, USA); Catherine Yen, César Boggiano, Dale Hu, Patrick Jean-Philippe, Que Dang, and Richard Hafner (NIAID DAIDS, Bethesda, MD, USA); Corey Casper (Access to Advanced Health Institute, Seattle, WA, USA); Debra Benator (Washington DC Veterans Affairs Medical Center, Washington, DC, USA); Deepak Kaushal (Texas BioMedical Research Institute, San Antonio, TX, USA); Dereck Tait (International AIDS Vaccine Initiative, New York, NY, USA); Richard Chaisson (Johns Hopkins University, Baltimore, MD, USA); Emily Douglass (Rutgers University, New Brunswick, NJ, USA); Georgia Tomaras (Duke University Medical Center, Durham, NC, USA); Gerald Voss (TuBerculosis Vaccine Initiative, Lelystad, Netherlands); Hans Spiegel (Contractor to NIAID); Justin Shenje (South African Tuberculosis Vaccine Initiative, Cape Town, South Africa); Katrin Eichelberg and Mamodikoe Makhene (NIAID Division of Microbiology and Infectious Diseases, Bethesda, MD, USA); Yasmin Mejia-Guevara (DLH Corporation, Atlanta, GA, USA); Lakshmi Ramachandra (NIH, Bethesda, MD, USA); Lesley de Armas and Savita Pahwa (University of Miami, Miami, FL, USA); Mark Harrington (Treatment Action Group, New York, NY, USA); Meg Trahey, One Dintwe, and Steve De Rosa (Fred Hutchinson Cancer Research Center, Seattle, WA, USA); Michael Saag (University of Alabama at Birmingham, Birmingham, AL, USA); Michael W Dunne (Gates MRI, Boston, MA, USA), Moises Huaman (University of Cincinnati, Cincinnati, OH, USA); Payam Nahid (University of California at San Francisco, San Francisco, CA, USA); Rada Savic (University of California, San Francisco School of Pharmacy and Medicine, San Francisco, CA, USA); Sai Majji (NIH National Institute of Child Health and Human Development, Bethesda, MD, USA); Simon Mallal (Vanderbilt Therapeutics, Nashville, TN, USA); Stephen Carpenter (Case Western University, Cleveland, OH, USA); Susan Swindells (University of Nebraska, Lincoln, NE, USA); Teri Roberts (Campaign for Access to Essential Medicines, Geneva, Switzerland); Vicki Godleski (Providence/Boston Center for AIDS Research, Providence, RI, USA); and Wolfgang Leitner (NIAID Division of Allergy, Immunology and Transplantation, Bethesda, MD, USA). Funding Information: GC, JGK, AG, and MDM led and wrote the Review, with support from Austin Van Grack (Social & Scientific Systems) under the overall direction of Judith Currier and Joseph Eron (AIDS Clinical Trials Group), Glenda Gray (HIV Vaccine Trials Network), Sharon Nachman (International Maternal Paediatric Adolescent AIDS Clinical Trials network), and Peter Kim and Sarah Read (NIAID Division of Aids [DAIDS]). The ACTG, HVTN, and IMPAACT provided support for developing the consensus statements. Funding was provided by National Institutes of Health (NIH) grants (UM1 AI 068636, UM1 AI068614, 5UM1AI154463, and UM1 AI 068636 to GC; UM1 AI068614-14 to JGK; and NIH UM1 AI069465 to AG). We gratefully acknowledge the contribution of the people who participated in various sessions: Austin Van Grack (DLH Corporation, Atlanta, GA, USA); Abdou Fofana (Boston University, Boston, MA, USA); Adrienne Shapiro, Chandler Church, and Chetan Seshadri (University of Washington, Seattle, WA, USA); Ann Ginsberg (Gates Foundation, Seattle, WA, USA); Catherine Yen, César Boggiano, Dale Hu, Patrick Jean-Philippe, Que Dang, and Richard Hafner (NIAID DAIDS, Bethesda, MD, USA); Corey Casper (Access to Advanced Health Institute, Seattle, WA, USA); Debra Benator (Washington DC Veterans Affairs Medical Center, Washington, DC, USA); Deepak Kaushal (Texas BioMedical Research Institute, San Antonio, TX, USA); Dereck Tait (International AIDS Vaccine Initiative, New York, NY, USA); Richard Chaisson (Johns Hopkins University, Baltimore, MD, USA); Emily Douglass (Rutgers University, New Brunswick, NJ, USA); Georgia Tomaras (Duke University Medical Center, Durham, NC, USA); Gerald Voss (TuBerculosis Vaccine Initiative, Lelystad, Netherlands); Hans Spiegel (Contractor to NIAID); Justin Shenje (South African Tuberculosis Vaccine Initiative, Cape Town, South Africa); Katrin Eichelberg and Mamodikoe Makhene (NIAID Division of Microbiology and Infectious Diseases, Bethesda, MD, USA); Yasmin Mejia-Guevara (DLH Corporation, Atlanta, GA, USA); Lakshmi Ramachandra (NIH, Bethesda, MD, USA); Lesley de Armas and Savita Pahwa (University of Miami, Miami, FL, USA); Mark Harrington (Treatment Action Group, New York, NY, USA); Meg Trahey, One Dintwe, and Steve De Rosa (Fred Hutchinson Cancer Research Center, Seattle, WA, USA); Michael Saag (University of Alabama at Birmingham, Birmingham, AL, USA); Michael W Dunne (Gates MRI, Boston, MA, USA), Moises Huaman (University of Cincinnati, Cincinnati, OH, USA); Payam Nahid (University of California at San Francisco, San Francisco, CA, USA); Rada Savic (University of California, San Francisco School of Pharmacy and Medicine, San Francisco, CA, USA); Sai Majji (NIH National Institute of Child Health and Human Development, Bethesda, MD, USA); Simon Mallal (Vanderbilt Therapeutics, Nashville, TN, USA); Stephen Carpenter (Case Western University, Cleveland, OH, USA); Susan Swindells (University of Nebraska, Lincoln, NE, USA); Teri Roberts (Campaign for Access to Essential Medicines, Geneva, Switzerland); Vicki Godleski (Providence/Boston Center for AIDS Research, Providence, RI, USA); and Wolfgang Leitner (NIAID Division of Allergy, Immunology and Transplantation, Bethesda, MD, USA). Publisher Copyright: © 2022 Elsevier Ltd
PY - 2022/11
Y1 - 2022/11
N2 - New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in developing tuberculosis vaccines for people with HIV, a series of symposia was held that posed six framing questions to a panel of international experts: What is the use case or rationale for developing tuberculosis vaccines? What is the landscape of tuberculosis vaccines? Which vaccine candidates should be prioritised? What are the tuberculosis vaccine trial design considerations? What is the role of immunological correlates of protection? What are the gaps in preclinical models for studying tuberculosis vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing tuberculosis vaccine development and the prioritisation of clinical trials for inclusion of people with HIV.
AB - New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in developing tuberculosis vaccines for people with HIV, a series of symposia was held that posed six framing questions to a panel of international experts: What is the use case or rationale for developing tuberculosis vaccines? What is the landscape of tuberculosis vaccines? Which vaccine candidates should be prioritised? What are the tuberculosis vaccine trial design considerations? What is the role of immunological correlates of protection? What are the gaps in preclinical models for studying tuberculosis vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing tuberculosis vaccine development and the prioritisation of clinical trials for inclusion of people with HIV.
UR - http://www.scopus.com/inward/record.url?scp=85140968531&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S2352-3018(22)00255-7
DO - https://doi.org/10.1016/S2352-3018(22)00255-7
M3 - Review article
C2 - 36240834
SN - 2352-3018
VL - 9
SP - e791-e800
JO - The lancet. HIV
JF - The lancet. HIV
IS - 11
ER -